Result of AGM

Cizzle Biotechnology Holdings PLC

16 June 2026

 

16 June 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Result of Annual General Meeting

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

Resolution	For*		Against		Votes withheld
	Total votes	%	Total votes	%
1. To receive the Company's annual report and accounts for the year ended 31 December 2025	137,411,997	99.97	45,606	0.03	13,090
2. To approve the Directors' Remuneration Policy	137,376,187	99.92	111,406	0.08	13,100
3. To approve the 2025 Remuneration Report	137,376,187	99.92	111,406	0.08	13,100
4. To re-appoint John Michael Treacy as a Director of the Company	128,097,905	93.17	9,389,698	6.83	13,090
5. To re-appoint Dawn Coverley as a Director of the Company	137,476,197	99.99	11,406	0.01	13,090
6. To re-appoint Nigel Ronald Lee as a Director of the Company	137,476,187	99.99	11,406	0.01	13,100
7. To re-appoint PKF Littlejohn LLP as auditor of the Company	137,476,197	99.99	11,406	0.01	13,090
8. To authorise the Directors to determine the auditor's remuneration	137,476,197	99.99	11,406	0.01	13,090
9. Authorise directors to allot shares for director option grants up to £2,064.56 nominal value	137,390,970	99.93	96,633	0.07	13,090
10. Authorise directors to allot 17,857,143 shares for conversion of £250,000 loan notes	137,376,455	99.93	96,623	0.07	27,615
11. Authorise directors to allot shares up to £14,165.44 until the next AGM or 15 months.	137,376,455	99.93	96,633	0.07	27,605
12. Disapply pre-emption rights for director option shares up to £2,064.56 nominal value.	137,330,884	99.90	142,194	0.10	27,615
13. Disapply pre-emption rights for 17,857,143 shares issued on loan note conversion.	137,330,884	99.90	142,194	0.10	27,615
14. Disapply pre-emption rights for specified allotments up to £14,165.44 until 2027 AGM or 15 months.	137,292,684	99.87	180,394	0.13	27,615
15. Allow general meetings, excluding AGMs, to be called with 14 clear days' notice.	137,376,197	99.92	111,406	0.08	13,090

*"Votes For" include votes giving the Chairman's discretion.

Enquiries:

Cizzle Biotechnology Holdings plc Allan Syms (Executive Chairman)	Via IFC Advisory
Allenby Capital Limited John Depasquale (Corporate Finance) Amrit Nahal (Sales and Corporate Broking)	[phone]
IFC Advisory Limited Tim Metcalfe Florence Staton	[phone]

About Cizzle Biotechnology

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood.  The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.  Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

END